Featured Trial
Esophagus and Stomach Cancer Treatment

Featured Trial
Liver Cancer Treatment

Featured Trial
Survey on COVID-19 Related Distress

Featured Trial
Self-Reported Data by Young Adults

Clinical and Administrative Resources

Web Application Portal

Submit an Inquiry

Update My Roster Profile

Other Research Resources

Resources for Active Trials

Mentoring Program

Group Meeting Presentations, Audit Tools, and User Groups

Specialty Presentation:
Integrating PROs in Trials

Specialty Presentation:
PRO Research Overview

Specialty Presentation:
Implementation Science

Latest News

January 30, 2023

Categories

News Stories

Now Enrolling: The BRIDGE research study is evaluating a new treatment approach for patients with early bladder cancer

January 24, 2023

Categories

News Stories

Blinatumomab significantly improves overall survival in newly diagnosed B-ALL patients who are MRD-negative after initial treatment (study E1910)

December 20, 2022

Categories

Announcements

The November/December 2022 News from ECOG-ACRIN blog is now available

December 19, 2022

Categories

News Stories

Blinatumomab Plus Consolidation Chemotherapy Significantly Reduces Risk of Death in MRD-Negative B-Cell ALL

December 15, 2022

Categories

News Stories

Study E1910 consolidates the role of blinatumomab in acute lymphoblastic leukemia (ALL)

Tweets

ECOG-ACRIN Cancer Research Group Follow

Biomarker-driven medical research involving adults who have or are at risk of developing cancer

ECOG-ACRIN Cancer Research Group @eaonc ·

22h

Researchers are studying a new treatment approach that may help reduce symptoms and prevent cancer growth in patients with #AnalCancer that has spread to other parts of the body. Learn more: https://bit.ly/ea2176-study #ancsm

Reply on Twitter 1620482796803264513 Retweet on Twitter 1620482796803264513 Like on Twitter 1620482796803264513 Twitter 1620482796803264513

ECOG-ACRIN Cancer Research Group @eaonc ·

23h

Could #greentea catechins help prevent the progression of #prostatecancer in men on active surveillance? #Clinicaltrial EA8184, led by Dr. Nagi Kumar of @MoffittNews, aims to find out. Learn more: https://bit.ly/ea8184trial #pcsm

Reply on Twitter 1620467368920027136 Retweet on Twitter 1620467368920027136 Like on Twitter 1620467368920027136 Twitter 1620467368920027136

ECOG-ACRIN Cancer Research Group @eaonc ·

31 Jan

#Clinicaltrial EA9152, led by Neil Palmisiano, MD of @RutgersCancer, is investigating the safety & efficacy of venetoclax, a BCL-2 inhibitor, in combination with vincristine sulfate in the relapsed or refractory #ALL population. More: https://bit.ly/EA9152 #leusm cc: @AcuteLeuk

Reply on Twitter 1620452010762899458 Retweet on Twitter 1620452010762899458 1 Like on Twitter 1620452010762899458 2 Twitter 1620452010762899458

About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More

ECOG-ACRIN by the Numbers

Active Clinical Trials

1300

Participating Institutions

International Sites

15000

Individual Members

Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).